Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
David WetherellPresident and Chief Operating Officer, Burrill Healthcare Venture and Private Equity Funds
David Wetherell has spent 20 years as a CEO in high-tech, as well as 17 years in venture capital, the last seven of which have been dedicated to biotech and life sciences. From 1986 to 2006, he served as both CEO and, later, chairman of CMGI, where he helped build the company from $3 million in annual revenues to more than $1 billion and started the first venture capital firm focused on the Internet, @Ventures. In 2003, due to the mapping of the human genome and demographic trends, Wetherell turned his attention to the life sciences.
In 2005, he started GBP Capital, a venture capital company focused exclusively on leading edge life sciences. Wetherell has received numerous awards, including Ernst & Young's New England Entrepreneur of the Year in 2000 and recognition as one of Money Magazine's Top 25 investors. He obtained his B.A. in Mathematics from Ohio Wesleyan University and an honorary doctorate from Bryant University. He currently serves as chairman of Lentigen and sits on the boards of numerous other companies, including HyperMed, Quintess, and Whiteglove Health.